Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RedHill's Antibiotic Approach For Crohn's Shows Promise, Caveats Remain

Executive Summary

Top-line data for a Phase III trial of RedHill's antibiotic combination for use in Crohn's disease show the study has hit its primary endpoint, but there is still some way to go before filings can be made for the novel approach.

You may also be interested in...

RedHill Unveils Plans For Pivotal Phase III Study For Crohn’s Therapy

RedHill Biopharma’s study results for its novel antibiotic approach to Crohn’s disease has left the company with some unanswered questions, despite hitting its endpoints in a recent Phase III study. Its COO, Gilead Raday, talks to Scrip about the next steps for the study.

Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows

The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.

Russia Approves First COVID-19 Vaccine

The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October. 


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts